文献速递食管与纵隔外科

系统性炎症与肌少症对食管癌患者生存的关联

Associations of Systemic Inflammation and Sarcopenia With Survival of Esophageal Carcinoma Patients.
PubMed 文献 · Ann Thorac Surg · 2020-04-09

高NLR合并肌少症者5年总生存为44.4%,5年癌症特异性生存为57.0%。

要点

  • 低NLR组中肌少症对生存无显著影响。
  • 高NLR合并肌少症者5年总生存44.4%,5年癌症特异性生存57.0%。

核心结论

  • 肌少症仅在高NLR(≥2.57)时与食管癌患者不良生存显著相关,两者联合有助于识别预后差的患者。

研究设计与样本

  • 回顾性队列研究,纳入378例接受食管切除术的食管癌患者,以队列NLR中位数2.57为截断值分组。
  • 肌少症依据术前CT计算的骨骼肌指数降低判定,采用单因素和多因素Cox风险模型分析预后因素。

主要发现

  • 高NLR合并肌少症者5年总生存为44.4%,5年癌症特异性生存为57.0%。

关键数值与推荐

  • NLR截断值为队列中位数2.57,高NLR定义为≥2.57,低NLR定义为<2.57。
  • 肌少症依据术前CT计算的骨骼肌指数降低判定。

临床怎么用

  • 对食管癌术前患者可联合评估NLR和肌少症,高NLR且肌少症者提示预后较差,需加强围手术期管理。

局限性

  • 回顾性研究设计,样本量378例,结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although both sarcopenia and systemic inflammation reportedly affect long-term outcomes of esophageal carcinoma (EC) patients, their reciprocal associations with survival outcomes have yet to be investigated. This study aimed to evaluate the survival impact of sarcopenia combined with the neutrophil-to-lymphocyte ratio (NLR) in EC patients undergoing esophagectomy. METHODS: In total, 378 EC patients were retrospectively reviewed. The cutoff value for NLR was set at the NLR median of the cohort. Sarcopenia was determined based on decreased skeletal muscle index calculated from computed tomography obtained before surgery. Univariate and multivariate Cox hazards models were applied to determine independent predictors of poor overall survival and cancer-specific survival. RESULTS: Sarcopenia was more common in the high-NLR group (2.57 or greater) than in the low-NLR group (less than 2.57; P = .01). In the high-NLR group, patients with sarcopenia had significantly poorer overall and cancer-specific survival than those without sarcopenia (P < .001). In contrast, there was no survival impact of sarcopenia in the low-NLR group. Patients with both high NLR and sarcopenia exhibited poor overall and cancer-specific survival (5-year overall survival = 44.4%, 5-year cancer-specific survival = 57.0%). Sarcopenia was independently associated with poor overall survival (hazard ratio = 1.95; P = .007) and poor cancer-specific survival (hazard ratio = 2.66; P = .002) as well as pathological stage III disease and noncurative resection in the high-NLR group. CONCLUSIONS: The survival and oncological impact of sarcopenia was noteworthy only when present with elevated NLR. The combination of 2 factors is rational for identifying EC patients likely to have poor survival outcomes.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sugawara K, Yagi K, Uemura Y, et al. Associations of Systemic Inflammation and Sarcopenia With Survival of Esophageal Carcinoma Patients. Ann Thorac Surg. 2020. PMID: 32278754. doi:10.1016/j.athoracsur.2020.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。